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Background: Nutrition support is essential in children with cancer, including
those undergoing bone marrow transplant (BMT), to reduce the risk of mal-
nutrition and associated deleterious outcomes. Enteral nutrition is more com-
monly provided via nasogastric than gastrostomy tubes because of safety con-
cerns with the latter in immunocompromised children. This systematic review
investigated the incidence and type of complications and outcomes in pediatric
cancer patients fed by gastrostomy.
Methods: Databases were searched for randomized and observational studies
investigating the use of any gastrostomy device in children aged <18 years with
any cancer diagnosis, including those undergoing BMT. Five cohort and 11 case
series studieswere included.Owing to clinical heterogeneity,meta-analyseswere
not performed.
Results: Quality of evidence varied, with five studies judged at serious risk of
bias and poor quality; however, the remaining 11 were considered to range from
moderate to good quality. Across studies, 54.6% of children developed one or
more complications, of which 76.6% were classified as minor, 23.4% major. The
most frequent complications included inflammation (52% of episodes), infection
(42.1%), leakage (22.3%), and granuloma (21%). Evidence regarding infection rates
in cancer/BMT patients compared with other disease states was inconclusive.
Gastrostomy feeding was associated with improvement or stabilization of nutri-
tion status in 77%–92.7% of children.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
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Conclusion: Gastrostomy feeding in this population is relatively safe and effec-
tive in stabilizing or improving nutrition status throughout treatment. Compli-
cations are frequent but mostly minor. Placement requires careful consideration
of the complications, benefits, nutrition risk and status at diagnosis, and quality
of life.
KEYWORDS
bone marrow transplantation, cancer, enteral nutrition, gastrostomy, pediatrics, systematic
review
INTRODUCTION
Malnutrition is a risk for children with cancer, including
those undergoing bone marrow transplant (BMT), with
the prevalence estimated at 5%–50%.1 Malnutrition has
been associated with reduced therapy tolerance, delayed
wound healing, increased risk of infection, longer hos-
pital stay, higher relapse rates, worse quality of life,
and graft-vs-host disease (GvHD), compared with those
who are adequately nourished at diagnosis and main-
tain a good nutrition status throughout treatment, in
pediatric cancer and BMT.2–8 The risk of malnutrition is
higher in children with advanced disease, metastatic solid
tumors, and higher treatment intensity, such as in high-
risk neuroblastoma, medulloblastoma, and BMT, com-
pared with nonmetastatic solid tumors and acute lym-
phoblastic leukemia treated with regimen A.9 Treatment
side effects include nausea, vomiting, anorexia, diarrhea,
andmucositis, which negatively impact nutrition intake.10
Combining these withmetabolic and psychological factors
exacerbates the risk of developing malnutrition.11 Child-
hood is a critical period for growth, bone formation, and
brain development.12 Consequently, optimal nutrition is
essential to support growth and development andmeet the
additional needs of disease.9
There are no international guidelines for nutrition sup-
port in pediatric cancer and BMT. However, the Ameri-
can Society for Parenteral and Enteral Nutrition (ASPEN)
and the European Society for Clinical Nutrition and
Metabolism (ESPEN) published guidelines for the nutri-
tion support of adult cancer and BMT patients in 2009
and 2021, respectively.13,14 These recommend enteral nutri-
tion as the first option for nutrition support in patients
with a functioning gastrointestinal tract. Enteral tube feed-
ing is an effective and safe method to minimize weight
loss during treatment,15 improve nutrition status and
energy intake during intensive treatment with minimal
complications,16,17 and maintain mucosal gut integrity,
thereby reducing bacterial translocation.18
In this population, enteral nutrition is most commonly
provided via nasogastric tubes (NGTs).18,19However, NGTs
are susceptible to complications, including discomfort
(particularly with mucositis), dislodgment with vomiting,
placement refusal, and contraindication due to mechan-
ical obstruction in the nasopharynx.18,20,21 These com-
plications can hinder the provision of adequate enteral
nutrition. Gastrostomy tubes avoid some of these com-
plications. They are fixed in place and so are less sus-
ceptible to dislodgment; can be hidden under clothes,
making them maybe more aesthetically acceptable21; and
have been associated with less use of parenteral nutri-
tion compared with use by children fed via NGT during
BMT.22 However, gastrostomy tubes have not commonly
been used in immunocompromised children because of
the risk of infectious complications.23 Although com-
plications associated with gastrostomy feeding, includ-
ing infection, have been shown in BMT24 and inflam-
matory skin events, skin erosion, and granuloma have
been shown in cancer populations,17,25 other studies
in this area have shown weight gain and only minor
complications.26,27
In this article, we systematically reviewed the evidence
relating to the complications and outcomes of gastros-
tomy use in this population. Findings will help guide clini-
cians’ decision-making when considering options to pro-
vide enteral nutrition. A narrative review investigating
indications, contraindications, complications, and man-
agement of gastrostomy tubes in children with cancer was
published in 2019.21However, a scoping search of the inter-
national prospective register of systematic reviews (PROS-
PERO) in July 2020 identified no systematic reviews previ-
ously published or underway in this area.
The primary objective of this review was to investigate
the incidence and type of complications associated with
gastrostomy use in children with cancer, including those
undergoing BMT. Secondary aimswere to evaluate the effi-
cacy of gastrostomies in relation to various nutrition and
clinical outcomes.
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METHODS
Protocol registration
The protocol for this review was written according to
the Preferred Reporting Items for Systematic Review
and Meta-Analyses Protocols (PRISMA-P)28 and reg-
istered with PROSPERO on September 28, 2020:
CRD42020211700. This systematic review adheres to
the PRISMA guidelines.29
Eligibility criteria
We included randomized controlled trials, controlled
(nonrandomized) clinical trials, prospective and retrospec-
tive cohort studies, case-control, and case series. Gray lit-
erature was included, if appropriate. Qualitative and ani-
mal studies, reviews, commentaries, and studies without
full-text availability were excluded. Authors of abstracts
for which a full-text article could not be found were con-
tacted to see if a full-text report existed. No restrictions
were imposed regarding date, country, language, or setting
of studies. Non-English studies were translated by known
healthcare professionals within our hospital.
Participants included children (<18 years, although we
accepted studies with an age range up to 21 years when
the average age was below 18) with any cancer diagnosis
receiving any treatment, including those undergoing BMT
from any donor or cell source for any diagnosis. If a study
included a mixed population—for example, of adults and
children—it was included if children’s data were reported
separately. If data were not reported in this way, authors
were contacted to request this information. The interven-
tionwas the use of any gastrostomydevice placed using any
technique.
Comparators were not essential for this review. Stud-
ies with no comparator were included, as these would
provide evidence on complications and outcomes of gas-
trostomy use. Comparators could include children with
cancer/BMT receiving nutrition support through various
routes, including NGT or parenteral nutrition. Regarding
complications, a comparator could include gastrostomy
use in noncancer/non-BMT disease states. Children with
neurological impairment have been considered the “refer-
ence population” in this circumstance17 because they will
not likely become immunocompromised, as is common in
those receiving cancer treatment/BMT, which poses a risk
for infectious complications.
Primary outcomes included the incidence and type of
any gastrostomy complications, investigated at any time
point until gastrostomy removal. Secondary outcomes
included awide range of nutrition and clinical parameters,
including nutrition intakes, anthropometry, survival, and
length of admission, that result from gastrostomy use, as
well as any comparator methods of nutrition support that
studies may have used.
Information sources and search
Databases searched via Ovid included MEDLINE (1946
onward), Embase (1974 onward), Cochrane Central Reg-
ister of Controlled Trials, AMED (1985 onward), and
CINAHL (via EBSCO). Gray literature searched included
EThOS (ethos.bl.uk) and Open Grey (www.opengrey.eu).
To strive for literature saturation, clinical expertswere con-
tacted in September 2020 for any further articles that could
have been missed from database searches, and reference
lists of included studies, relevant reviews,30,31 and the table
of contents of key journals Pediatric Blood & Cancer and
Journal of Pediatric Hematology/Oncology from January
2019 (dates since the most recent nonsystematic review)21
were scanned.
The search strategy was developed in consultation with
a Health Sciences Research Librarian. One author (J.E.)
searched all sources. The final MEDLINE (Ovid) search
strategy (Supplementary Material S1) was adapted for use
with other databases. The last search was run on Septem-
ber 18, 2020.
Study selection
Studies were managed using Covidence32 and references
using Mendeley.33 Search results were imported from
databases into Covidence and duplicates removed and
then checked manually to remove missed duplicates and
multiple study reporting. References were independently
screened by two authors (J.E. and B.G.) against the eligi-
bility criteria, first on title and abstract and second on full-
text reports of studies that appeared eligible. When neces-
sary, study authors were contacted to resolve uncertainty
around eligibility.
Data items and extraction
Data were extracted independently by two authors (J.E.
and B.G.) using a custom extraction Excel spreadsheet.
Data were extracted on general information (author, coun-
try, funding, conflicts of interest, study design), population
(inclusion/exclusion criteria, patient characteristics, sam-
ple size), interventions (type of gastrostomy), comparators,
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(other nutrition support interventions), and outcomes
(gastrostomy complications and classification, time points,
nutrition and clinical parameters). Study authors were
contacted up to a maximum of three times via email to
resolve any uncertainties or obtain missing information.
Risk-of-bias assessment
The search identified only observational studies. There-
fore, the Risk of Bias in Non-randomized Studies of
Interventions (ROBINS-I)34 tool was used to assess
studies in which participants were not randomized to
comparison groups. Domains include confounding, partic-
ipant selection, classification of interventions, deviations
from intended interventions, missing data, measurement
of outcomes, and selection of reported results. Bias in each
domain was classified as “low,” “moderate,” “serious,”
“critical,” or “no information” according to responses to
signaling questions. Each study was given an overall risk
of bias equivalent to the most severe level in any domain.
Studies without comparison groups were assessed using
the National Institutes of Health (NIH) quality assess-
ment tool for before-after (pre-post) studieswith no control
group.35 Criteria include how clearly the research ques-
tion, population, intervention, outcomes, statistical meth-
ods, sample size, and results are described. Each study was
given an overall rating of “good,” “fair,” or “poor.” The risk
of bias was assessed independently by two authors (J.E.
andB.G.) at the study level. Disagreements regarding study
selection, data extraction, and risk-of-bias assessmentwere
resolved by consensus between the two authors, with a
third author (G.O.C.) acting as arbiter, if required.
Included studies that compared groups were clinically
heterogeneous regarding populations, interventions, and
outcomes. Therefore, meta-analyses were not undertaken,




Database searches yielded 8240 studies. Two additional
studies were identified through other sources. After
removing duplicates, 7664 studies remained. Following
screening on title and abstract, 7592 were excluded for not
meeting the eligibility criteria. The full text of the remain-
ing 72 studies was screened for eligibility. Of these, 16 arti-
cles with data on 681 children with gastrostomies were
included (Figure 1).
Study characteristics
One study was translated from French36; others were in
English. All but two studies17,36 were single-center, with
50% (8 of 16) undertaken in Europe,17,22,26,36–40 44% (7 of 16)
in North America,24,25,27,41–44 and one in Australia.45 Study
inclusion periods ranged from3.5 to 16 years,25,26with aver-
age ages from 2 to 13 years.24,36,40 Two studies focused
on children undergoing BMT,22,24 three investigatedmixed
populations undergoing cancer treatment with and with-
out BMT,26,27,38 and 69% (11 of 16) included children under-
going treatment for various malignant diseases without
BMT.
No studies were randomized, 69% (11 of 16) were
case series following one group only (seven were
retrospective,25,27,38,40,43–45 whereas four did not state
whether they were retrospective or prospective26,37,41,42),
and 31% (5 of 16) were cohort studies17,22,24,36,39 comparing
two groups (only one was prospective39). Compara-
tor groups included children with gastrostomies for
noncancer/non-BMT reasons (typically neurological
impairment17,24,39) or NGT during cancer treatment
without17 or with BMT.22 Interventions varied across
studies; 50% (8 of 16) used percutaneous endoscopic
gastrostomies17,22,24,26,36,38,43,45; 31% (5 of 16) used mixed
devices and insertion techniques, including buttons,
surgical, open and interventional radiology,25,27,41,42,44
with others using percutaneous radiologic-,40 video-,39
or laparoscopy-aided buttons.37 Four studies compared
complications by insertion technique and device.25,41,42,44
Gastrostomies were placed prophylactically to preempt
nutrition problems during BMT22,24 or mucositis45 or in
children with preexisting malnutrition who are therefore
at high nutrition risk at diagnosis.17,36,39,40 Other indica-
tions included anorexia, reduced dietary intake andweight
loss during treatment, and unsafe oral feeding.26,27,38,41
Studies reported gastrostomy insertion ranging from 1.5
to 7.417,26,27,45 months after diagnosis. In two studies, they
were placed 2222 and 56.524 days pre-BMT. The aver-
age duration of gastrostomy use was 10 months (range,
6.3–12.925,26). All studies reported gastrostomy complica-
tions, 11 reported various clinical and nutrition outcomes.
Included studies are summarized in Table S1.
Study quality
Studies comparing groups were assessed as being
at serious17,36 and moderate22,24,39 risk of bias using
ROBINS-I.34 Studies with no comparator were assessed
as poor,26,37,41 fair,38,42,45 or good25,27,40,43,44 quality using
the NIH tool.35 Common methodological weaknesses
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F IGURE 1 Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) flow diagram showing studies included in
the systematic review
included the absence of randomization, retrospective
study designs limiting the accuracy and reliability of data
(particularly complications), small samples (no studies
provided sample size/power calculations), lack of detail
regarding participant selection, and outcomes that were
not clearly prespecified. The risk-of-bias assessments are
shown in Tables S2 and S3.
Incidence and timing of complications
Complications were categorized as major or minor in 69%
(11 of 16) of studies according to each author’s own criteria
(Table S4). Across all studies, 54.6% (n = 351) of patients
developed one or more complications, of which 27.4%
(n = 46) developed a major complication. Of complication
episodes, 23.4% (n = 88) were major, and 76.6% (n = 472)
were minor (Table 1). In the 11 studies on children with
cancer not undergoing BMT, 59.4% (n = 336) of patients
developed one or more complications, of which 12.2% (n=
32) developed a major complication. Of the episodes, 7.3%
(n = 74) were major, and 92.7% (n = 471) were minor. Of
the two BMT studies,22,24 28.4% (n = 15) of patients devel-
oped one or more complications, of which 95.5% (n = 14)
developed a major complication. Of the episodes, 95.5%
(n = 14) were major. No minor complications occurred in
one study,24 whereas 9.1% (n = 1) were minor in the other.
One study reported complications according to under-
lying cancer diagnosis, with 63% (n = 64) of patients hav-
ing central nervous system tumors, 60% (n= 27) with solid
tumors, and 60% (n= 15) with leukemia/lymphoma devel-
oping a complication.25
Studies reported complications at differing time points











TABLE 1 Incidence of complications across studies
Author
Patients that developed
≥1 complication, n (%)
Total complication
episodes, n
Patients that developed a





Evans (2019)22 11 (20.4) 11 10 (90.9) 10 (90.9) 1 (9.1)
Henry (2017)36 37 (63.8) 82 Not reported 8 (9.8) 74 (90.2)
Hamilton (2017)44 40 (53.3) Cannot determine 12 (30.0) Cannot determine Cannot determine
Fernandez-Pineda
(2016)25
106 (61.9) 177 Not reported 46 (26.0) 131 (74.0)
Richioud (2015)40 2 (18.2) 2 0 (0) 0 (0) 2 (100)
Kaur (2013)24 4 (36.4) 4 4 (100) 4 (100) 0 (0)
Schmitt (2012)17 46 (62.2) 75 10 (21.7) 10 (13.3) 65 (86.7)
Parbhoo (2011)45 12 (85.7) 49 3 (25.0) (systemic) 3 (6.1) (systemic) 46 (93.9) (local)
Arnbjornsson
(2006)39
Cannot determine Cannot determine Not defined Not defined Not defined
Bakish (2003)43 16 (64.0) 25 2 (12.5) 2 (8.0) 23 (92.0)
Skolin (2002)38 Not reported 88 Not defined Not defined Not defined
Barron (2000)27 21 (47.7) Not reported 3 (14.3) 3 (cannot determine) Not defined
Pedersen (1999)26 23 (71.9) 55 0 (0) 0 (0) 55 (100)
Arnbjornsson (1999)37 3 (33.3) 6 0 (0) 0 (0) 6 (100)
Mathew (1996)42 30 (90.9) 71 2 (6.7) 2 (2.8) 69 (97.2)
Aquino (1995)41 Not reported 57 Not defined Not defined Not defined
Total (%) 351 (54.6) 702 46 (27.4) 88 (23.4) 472 (76.6)
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TABLE 2 Incidence of gastrostomy site infectious complications
Author
Peritubal wound
infection, n episodes (%
total episodes)
Peritubal wound
infection, n patients (%
total patients)
Peritubal wound
inflammation, n episodes (%
total episodes)
Evans (2019)22 11 (100) 11 (20.4) Not reported
Henry (2017)36 16 (19.5) Not reported 63 (76.8)
Hamilton (2017)44 Not reported Not reported Not reported
Fernandez-Pineda (2016)25 42 (23.7) Not reported Not reported
Richioud (2015)40 0 (0) 0 (0) Not reported
Kaur (2013)24 4 (100) 4 (36.4) Not reported
Schmitt (2012)17 6 (8.0) Not reported 29 (38.7)
Parbhoo (2011)45 16 (32.7) 9 (64.3) 4 (8.2)
Arnbjornsson (2006)39 5 (cannot determine) Not reported Not reported
Bakish (2003)43 23 (92.0) 15 (60.0) Not reported
Skolin (2002)38 57 (64.8) 18 (100) Not reported
Barron (2000)27 Not reported 18 (40.9) Not reported
Pedersen (1999)26 23 (41.8) 12 (37.5) Not reported
Arnbjornsson (1999)37 0 (0) 0 (0) Not reported
Mathew (1996)42 Not reported 15 (45.5) 23 patients (69.7)
Aquino (1995)41 13 (22.8) 9 (36.0) 38 (66.7)
Total (%) 216 (42.1) 111 (40.1) 157 (52.0)
within 1 week of placement in 21.4%45 and 50%24 of
patients, within 1 month in 18.5% of patients39 and 20.3%
of episodes,25 within 2 months in 100% of patients,24 and
within 6 months in 29.6% of patients.39
Mechanical complications
Mechanical and other noninfectious gastrostomy compli-
cations accounted for a small proportion of total episodes,
including buried bumper syndrome, bleeding, gastrocu-
taneous fistula, tube occlusion, dislodgment, migration,
breakage (all <7%), pain/discomfort (15.8%), granuloma
(21.0%), and peristomal leakage (22.3%) (Table S5).
Infectious complications
Infection and inflammation made up the largest propor-
tion of total episodes (42.1% and 52.0%, respectively), and
40.1% of patients with a gastrostomy experienced an infec-
tion (Table 2). Across the 11 studies on children with can-
cer not undergoing BMT, gastrostomy site infections made
up 30.5% (n = 201) of complication episodes, occurring in
42.7% (n= 96) of patients. In the two BMT studies,22,24 gas-
trostomy site infectionsmade up 100% (n= 14) of complica-
tion episodes, occurring in 28.4% (n= 14) of patients. In all
cases, infections were successfully treated using oral, local,
or intravenous antibiotics.
Peritonitis occurred in 1.2%36 and 4.0%43 of total
episodes, and abdominal wall abscess occurred in 4.0%36,43
of total episodes. Gastrostomy removal was required
because of infection in 2.3%–27.3%24,27 of patients, the lat-
ter being one of the BMT studies. No child required gas-
trostomy removal because of infection in the other BMT
study.22 Infections were more common after 1 month after
gastrostomy insertion (31 episodes vs 11 within the first
month)25 and occurred, on average, 1.526 and 5.245 months
postinsertion. All infections occurred within 2 months of
placement in another study.24
Three studies compared complications between chil-
dren with gastrostomy for cancer/BMT and those with
neurological disability.17,24,39 Whereas significantly higher
inflammatory episodes were found in one study (38.7%
total episodes oncology vs 17.5% neurology group, P =
.049)17 and infections in another (36.5% in BMT vs 3.3%
comparator group, P = .01),24 no difference in infec-
tion rates were seen in other studies.17,39 No differences
between groups were seen for other complications, includ-
ing leakage, granuloma,17,39 and material complications.17
Insertion technique and device
Three studies41,42,44 found no difference between gastros-
tomy insertion technique and type or number of com-
plications, yet one25 found significantly more infections
with open vs endoscopic/laparoscopic techniques (P =
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.003). Local infections were more frequent with a button
than with balloon devices (P = .05),42 whereas another
study reported no significant difference between total com-
plication episodes with button devices (64.2%) vs tubes
(52.3%).25
Nutrition outcomes
Height z-score decreased in two studies, from+0.8 at diag-
nosis to −0.2 at end of follow-up (P-value not reported)17
and from +0.03 at gastrostomy placement to −0.3 1 year
after (P-value not reported).38 A significant increase in
mean weight from gastrostomy placement to 1 month
(P = .018) and 3 months postplacement (P < .0001) was
shown in one study,27 with others showing weight gains in
42.4%–73.0%17,42 of patients during gastrostomy feeding42
and 73% of patients 3 months after placement.40 Gas-
trostomy feeding also facilitated weight gain in malnour-
ished children, with 50% and 77% gaining weight at 1 and
3 months postplacement, respectively,27 and 60% reach-
ing ideal body weight after 5 months.41 Weight z-score
significantly increased from gastrostomy placement to
1 (P = .04),38 2 (P = .039),38 and 6 (P < .05)45 months post-
placement; however, a nonsignificant change was seen at
6 months postplacement (P = .054) in another study.26
Two studies22,36 showed stability of nutrition status via
gastrostomy and NGT but no difference between either
on change in weight z-scores from BMT admission to dis-
charge (P = .379)22 and body mass index (BMI) z-scores
from diagnosis to 6–12 months after treatment completion
(P = .09).36 Children fed via gastrostomy, compared with
those fed via NGT, did not require parenteral nutrition as
often during BMT admission (P = .049).22 However, for
children that needed parenteral nutrition, one study found
similar duration between children fed via gastrostomy and
those fed via NGT (P = .140),22 whereas another showed
shorter duration during cancer treatment for those fed via
gastrostomy rather than via NGT (P = .0038).36
One BMT study found no difference between children
fed via gastrostomy and those fed via NGT on the change
in serum albumin level throughout admission or in the
number of patients developing hypoalbuminemia ≤30 g/L
(88.9% vs 84.6%, respectively; P = .620).22 Nutrition out-
comes are summarized in Table 3.
Clinical outcomes
Two studies found no difference in the length of admission
for children fed via gastrostomy vs those fed via NGT—one
during BMT (45 vs 46 days respectively, P= .625)22 and the
other on an average length of admission throughout can-
cer treatment pregastrostomy and postgastrostomy (9.1 vs
8.2 days, respectively; no P-value reported).43 No signifi-
cant differences were found between gastrostomy vs NGT
on day 100 in overall mortality (0% vs 5.5%, respectively;
P= .081)22, nonrelapse mortality (0% vs 4.4%, respectively;
P = .120),22 or event-free survival at 4 years (74% vs 85%,
respectively; P = .31).36 One BMT study found no differ-
ence between children fed via gastrostomy and those fed
viaNGTonGvHDgrades III–IV (3.7% vs 6.6%, respectively;
P = .664) and gut GvHD (3.7% vs 9.9%, respectively; P =
.191).22 Clinical outcomes are summarized in Table 3.
DISCUSSION
We present the first systematic review investigating the
incidence and type of complications and outcomes of gas-
trostomy use in children with cancer, including those
undergoing BMT. Gastrostomies were associated with fre-
quent complications in∼50% of children (75% beingminor,
25% major) and stabilization or improvement in nutrition
status for the majority of children.
Complications
The classification of complications as minor or major
was nonstandardized, leading to discrepancies between
studies. Any infection was classified as minor in three
studies26,43,44 and major in two25,40; if treated with intra-
venous antibiotics, infection was classified as minor36 in
one study yet major in others.17,22,24 In immunocompro-
mised children, even a local infection could be viewed as
a major event.24 Other studies defined major complica-
tions by unplanned events—for example, a hospital admis-
sion or interventional procedure.17,42,44 Different defini-
tions have led to variations in major complications from
6.1%–17.5% in noncancer populations.46
The most frequent complications were inflammation
and infection of the gastrostomy site, comprising 40%–
50% of total episodes. Significantly more infections were
seen in 11 children undergoing BMT compared with those
not undergoing BMT.24 Comparatively, no difference was
seen in two studies with a combined sample of 101 under-
going cancer treatment (without BMT), compared with
neurologically impaired children,17,39 and a further study
found five children with BMT had no more complica-
tions than their wider population.26 As with the clas-
sification of complications, the differentiation between
local infection and inflammation at the gastrostomy site
also varied between studies. Some used a positive culture
for microorganisms to confirm an infection,26,27,38,41,42,45
with others using clinician diagnosis alone to make the
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TABLE 3 Nutrition and clinical outcomes of gastrostomy feeding
Outcomes and authors Time period Results P
Weight-for-height z-score
Schmitt (2012)17 Placement to end of enteral nutrition +0.8 Not reported
Weight-for-age z-score
Evans (2019)22 BMT admission to discharge Gastrostomy: 0.0; nasogastric: −0.1 .379
Parbhoo (2011)45 Placement to 5 months after Maintained (no data) Not reported
Removal to 6 months after Increased −1.04 to −0.53 <.05
Skolin (2002)38 Placement to 1 month after +0.03 .04
Placement to 2 months after +0.11 .039
Placement to 3, 6, 12 months after −0.04, −0.12, +0.24 Not reported
Pedersen (1999)26 Placement to 6 months after +0.3 .054
Weight, kg
Schmitt (2012)17 Placement to end of enteral nutrition 73.0% gained, 4.1% maintained, 23.0% lost Not reported
Richioud (2015)40 Gastrostomy placement to 1 month after 64.0% gained, 18.0% maintained, 9.0% lost Not reported
Barron (2000)27 Gastrostomy placement to 1 month after 38.6% gained, 54.0% maintained, 6.8% lost .018
Placement to 3 months after 69.2% gained, 28.2% maintained, 2.6% lost <.0001
Mathew (1996)42 During gastrostomy feeding 42.4% gained, 39.0% maintained, 18.0%
lost
Not reported
Aquino (1995)41 Placement to removal Increase 12.9% desirable body weight Not reported
BMI z-score
Henry (2017)36 Diagnosis to end of treatment Gastrostomy: −0.09; nasogastric: −0.13 >.05
Diagnosis to 6–12 months after treatment Not reported .09
Height z-score
Schmitt (2012)17 Diagnosis to end of follow-up Decreased +0.8 to −0.2 Not reported
Skolin (2002)38 Gastrostomy placement to 1 year after Decreased +0.03 to −0.3 Not reported
Survival
Evans (2019)22 Overall survival 100 days post-BMT Gastrostomy: 0%; nasogastric: 5.5% .081
Nonrelapse mortality 100 days post-BMT Gastrostomy: 0%; nasogastric: 4.4% .120
Henry (2017)36 Event-free survival at 4 years Gastrostomy: 74.0%; nasogastric: 85.0% .31
Length of admission
Evans (2019)22 Days between BMT to discharge Gastrostomy: 45 days; nasogastric: 46 days .625





Evans (2019)22 Requirement during BMT admission Gastrostomy: 68.5%; nasogastric: 81.3% .049
Days provided during BMT admission Gastrostomy: 31 days; nasogastric: 31 days .140
Henry (2017)36 Days provided during admission Gastrostomy: 5.8 days; nasogastric: 9.9
days
.0038
Abbreviations: BMI, body mass index; BMT, bone marrow transplant.
distinction.17,22,24,25,36,39,43 Certainly, from included stud-
ies, the potential for episodes of infection and inflamma-
tion to be misclassified was a possibility. Distinguishing
between gastrostomy site infection and inflammation can
be challenging in clinical practice, particularly in some
cases in which these complications may coexist.
Risks associated with infections included neutrope-
nia. No association was found between absolute neu-
trophil count (ANC) at gastrostomy placement and
infection in two studies,25,39 whereas another found
50% of patients were neutropenic (ANC < 1000) at
placement.24 At time of infection, neutropenia (ANC <
500–1500) was found in 71.4%–75% of patients24,38 and
23.8%–100% of episodes.25,26,41,45 Compared with those
who are adequately nourished, malnutrition has also
been associated with more frequent infection in pedi-
atric cancer patients.4,45,47 However, one study found
more gastrostomy infections in the BMT, compared
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with the comparator group (with gastrostomies but not
undergoing BMT) but no difference between groups on
weight z-scores, suggesting neutropenia was the main
contributor.24
Because of mixed evidence, it is difficult to draw
conclusions regarding the timing of complications, gas-
trostomy devices, and insertion techniques. About 20%–
50% of complications were seen within the first month
after gastrostomy placement24,25,39,45 and 30%–80% after
1 month.25,39,45 Local infections were more frequent
with buttons than with tube devices in one study42;
however, another reported no difference.25 Open rather
than endoscopic/laparoscopic technique was associated
with infections in one study,25 although three found no
difference.41,42,44 This supports a recent systematic review
that found no difference between these insertion tech-
niques in children.48
Outcomes
Gastrostomy feeding was associated with improvement or
stabilization of nutrition status in 77%–92.7% of children,
with 50%–77% ofmalnourished children gaining or achiev-
ing ideal bodyweight27,41; these are important results given
that malnourished children have associations with lower
survival rates.7 Equivalent changes in nutrition statuswere
seen, compared with NGTs.22,36 However, in many stud-
ies, parenteral nutrition was provided alongside gastros-
tomy and NG feeding,22,26,27,36,38 which will have con-
tributed to results. In the studies comparing gastrostomy vs
NGT, gastrostomy use was associated with less parenteral
nutrition during BMT admission22 and throughout cancer
treatment,36 possibly owing to gastrostomies avoiding cer-
tain complications ofNGT such as refusal and dislodgment
with vomiting,18,22 suggesting that gastrostomy, rather
than NG feeding, played a greater role in supporting nutri-
tion status. However, it is not the gastrostomy, per se, that
facilitates benefits to nutrition status, but enteral nutrition.
Few studies detailed the volume and type of enteral nutri-
tion provided. Proactive enteral nutrition, given systemat-
ically in one center compared with another where this was
not initiated, has prevented rapid weight loss at the begin-
ning of chemotherapy and stabilizedweight during follow-
up in children with bone tumors.17 Enteral nutrition ini-
tiated systematically on day 1 post-BMT, compared with
parenteral nutrition initiated at the same time, has also
reduced hospital stay and improved survival in BMT.49,50
Less parenteral nutrition with gastrostomy use has eco-
nomic and safety implications, given the cost of parenteral
nutrition51 and avoidance of parenteral nutrition–related
complications.19,52
Most studies assessed nutrition status using
weight17,22,27,38,40–42,45 and BMI,36 which have limita-
tions in this population, as they can be distorted by tumor
mass and hydration status.53More sensitivemethods, such
as mid-upper arm circumference, which is independent
of such confounding factors,7,53 should be used in future
studies.
Limitations
Limitations of the evidence include retrospective designs,
small samples, absence of randomization, lack of com-
parator groups (meaning meta-analyses were not con-
ducted), and heterogeneity regarding populations, gas-
trostomy devices and insertion techniques, classification
of complications, and varying follow-up. Within studies,
there was also an absence of subgroup analysis of compli-
cations and outcomes specific to underlying cancer diag-
nosis and treatment modality other than BMT. Conse-
quently, the level of evidence varied, with five included
studies judged at serious risk of bias and poor quality.How-
ever, the majority were judged as better quality, with the
remaining 11 studies considered at moderate risk of bias to
good quality. Nevertheless, this review provides the most
accurate estimation of gastrostomy complications and out-
comes in this population based on the currently best avail-
able evidence.
Implications for practice
In agreement with other authors,17,27,36,38,41–43 this review
suggests gastrostomy use is relatively safe and associ-
ated with mostly minor complications and improvements
in nutrition status. Consequently, we recommend gas-
trostomies could be placed, following careful considera-
tion, prophylactically at diagnosis in specifically selected
children—for example, those with existing malnutrition
and diagnoses of high nutrition risk, as well as in prepa-
ration for intensive treatment protocols such as BMT,54
for which severe mucositis and long-term enteral nutri-
tion are anticipated, and improvements might be seen in
quality of life. Even though gastrostomies are more inva-
sive than NGTs, the aesthetic benefit has been shown to
aid acceptability to overcome resistance to tube feeding42,43
and relieve stress, enabling families to concentrate on oth-
ers aspects of life.26,38 Proactive placement enables the
wound to heal before neutropenia, and enteral nutrition
to begin at the earliest need. Given many complications
that might have been avoided with better care,26,38 families
should receive gastrostomy education, and children should
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be monitored closely during neutropenia to minimize
complications.
Implications for research
Further research should include prospective, multicen-
ter trials to obtain adequately powered samples and pro-
vide higher-quality evidence. Gastrostomy complications
should be compared between children with cancer and
noncancer populations, with neurologically impaired chil-
dren considered the “reference population.”17,55 Random-
izing such studies would not be possible, but uniform
methods for classifying complications and consistent time
points for follow-up should be applied. Future research
should also investigate gastrostomy education strategies.
Although education protocols have shown improvements
in care in a preprotocol vs postprotocol evaluation, they
have not shown reductions in complications,56 which
future research should prioritize. Gastrostomy outcomes
should be compared within cancer/BMT populations but
including children fed via other routes, such as NGTs
and parenteral nutrition. These trials should be random-
ized, detail the nutrition support strategy, and inves-
tigate outcomes, including nutrition intake and status
(using sensitive measures), quality of life, and economic
evaluation.
CONCLUSION
In conclusion, this review has shown gastrostomy use in
children with cancer, including those undergoing BMT, is
relatively safe, associated with frequent but mostly minor
complications, and effective in stabilizing or improving
nutrition status throughout treatment. The decision to
place a gastrostomy requires careful consideration of the
risks and benefits, including the complications and out-
comes reported here, as well as the nutrition risk of the
child’s diagnosis, treatment intensity, nutrition status at
diagnosis, expected length of enteral nutrition, and qual-
ity of life.
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